Antibiotic induced liver injury: what about children?

REFERENCES

• Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774–85.
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000;15(5):480–8.
   PubMed Web of Science ®Google Scholar
• Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–55.
   PubMed Web of Science ®Google Scholar
• Larrey D. Drug-induced liver diseases. J Hepatol. 2000;32:77–88.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al.. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.
   PubMed Web of Science ®Google Scholar
• de Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol. 2004;58(1):71–80.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34.
   PubMed Web of Science ®Google Scholar
• Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76.
   PubMed Web of Science ®Google Scholar
• Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16(23):3041–53.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003–9.
   PubMed Web of Science ®Google Scholar
• Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol. 2005;39(4 Suppl 2): S83–9.
   PubMed Web of Science ®Google Scholar
• Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 2007;150(6):808–15.
   PubMed Web of Science ®Google Scholar
• Fréneaux E, Labbe G, Letteron PThe Le Dinh, Degott C, Genève J, et al.. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicularsteatosis induced by this antibiotic. Hepatology. 1988;8(5):1056–62.
   PubMed Web of Science ®Google Scholar
• Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;12(2):113–24.
   PubMedGoogle Scholar
• Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–76.
   PubMed Web of Science ®Google Scholar
• Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010;11(5):607–11.
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, et al.. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9.
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Bhatnagar P, Graham J, Henderson J, Leathart JB, Pirmohamed M, et al.. Proceedings of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31–Nov 4; San Francisco, CA, USA. Hepatology. 2008;48:396A–7A.
   Google Scholar
• Hautekeete ML, Horsmans Y, van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al.. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117(5):1181–6.
   PubMed Web of Science ®Google Scholar
• O’Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al.. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717–20.
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, et al.. Liver injury related to amoxycillin–clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol. 1995;22(1):71–7.
   PubMed Web of Science ®Google Scholar
• Levy C, Lindor KD. Drug-induced-cholestasis. Clin Liver Dis. 2003;7(2):311–30.
   PubMedGoogle Scholar
• Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73–96.
   PubMedGoogle Scholar
• Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al.. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15.
   PubMed Web of Science ®Google Scholar
• Lucena MI, García-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22(2):141–58.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al..; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.
   PubMed Web of Science ®Google Scholar
• Kramer MS. Assessing causality of adverse drug reactions: global introspection and its limitations. Drug Inf J. 1986;20:433–7.
   Google Scholar
• Macedo AF, Marques FB, Ribeiro CF. Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs? Drug Saf. 2006;29:697–702.
   PubMed Web of Science ®Google Scholar
• Goldstein LI, Ishak KG. Hepatic injury associated with penicillin therapy. Arch Pathol. 1974;98(2):114–7.
   PubMedGoogle Scholar
• Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci. 1981;26(5):470–3.
   PubMed Web of Science ®Google Scholar
• Oñate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, González de Zárate P, Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis. 1995;20(2):474–5.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Guilarte J, Salmerón FJ, Lucena MI, Bellot V. Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother. 2001;35(6):783–4.
   PubMed Web of Science ®Google Scholar
• Köklü S, Yüksel O, Filik L, Usküdar O, Altundag K, Altiparmak E. Recurrent cholestasis due to ampicillin. Ann Pharmacother. 2003;37(3):395–7.
   PubMed Web of Science ®Google Scholar
• Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens–Johnson syndrome. An ampicillin-associated case. Gastroenterology. 1990;99(3):854–6.
   PubMed Web of Science ®Google Scholar
• Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994;20(1):112–6.
   PubMed Web of Science ®Google Scholar
• Schwarze C, Schmitz V, Fischer HP, Sauerbruch T, Spengler U. Vanishing bile duct syndrome associated with elevated pancreatic enzymes after short-term administration of amoxicillin. Eur J Gastroenterol Hepatol. 2002;14(11):1275–7.
   PubMed Web of Science ®Google Scholar
• Madroñero AB, Porcel JM, Bielsa S. Hepatotoxicity induced by amoxicillin. Rev Esp Enferm Dig. 2007;99(3):173–4.
   PubMed Web of Science ®Google Scholar
• Romney R, Biour M, Belloula D, Elbaz D, Carriere J, Cadranel JF. Amoxicillin induced acute hepatitis. Gastroenterol Clin Biol. 2004;28(5):505–6.
   PubMedGoogle Scholar
• García Rodríguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156(12):1327–32.
   PubMedGoogle Scholar
• Köklü S, Köksal AS, Asil M, Kiyici H, Coban S, Arhan M. Probable sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother. 2004;38(12):2055–8.
   PubMed Web of Science ®Google Scholar
• Hussaini SH, O’Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007;19(1):15–20.
   PubMed Web of Science ®Google Scholar
• Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70(5):721–8.
   PubMed Web of Science ®Google Scholar
• Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–9.
   PubMed Web of Science ®Google Scholar
• Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects — review of the literature. Eur J Med Res. 2001;6(4):139–49.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al.. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850–6;
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Alonso A, García-Cortes M, García-Ruiz E, Benitez R, et al.. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603–12;
   PubMed Web of Science ®Google Scholar
• Ten Pass A, Quinn EL. Cholestatic hepatitis following the administration of sodium oxacillin. JAMA. 1965;191:674–5.
   PubMed Web of Science ®Google Scholar
• Freedman M. Oxacillin: apparent hematologic and hepatic toxicity. Rocky Mt Med J. 1965;62:34–6.
   PubMedGoogle Scholar
• Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr. 1976;89(5):835–8.
   PubMed Web of Science ®Google Scholar
• Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis. 2002;34(1):50–4.
   PubMed Web of Science ®Google Scholar
• Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. South Med J. 2002;95(6):650–2.
   PubMed Web of Science ®Google Scholar
• Nahata MC, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. Dev Pharmacol Ther. 1982;4(3–4):117–23.
   PubMedGoogle Scholar
• Lee CY, Chen PY, Huang FL, Chi CS. Reversible oxacillin-associated hepatitis in a 9-month-old boy. J Paediatr Child Health. 2008;44(3):146–8.
   PubMed Web of Science ®Google Scholar
• Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60(1):76–82.
   PubMed Web of Science ®Google Scholar
• Li L, Jick H, Jick SS. Updated study on risk of cholestatic liver disease and flucloxacillin. Br J Clin Pharmacol. 2009;68(2):269–70.
   PubMed Web of Science ®Google Scholar
• Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf. 2003;2(3):287–304.
   PubMedGoogle Scholar
• Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, et al.. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology. 2010;51(5):1656–64.
   PubMed Web of Science ®Google Scholar
• Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasisin children. Lancet. 1988;2(8625):1411–3.
   PubMed Web of Science ®Google Scholar
• Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al.. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 1999;88(12):1352–5.
   PubMed Web of Science ®Google Scholar
• Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol. 2009;15(21):2669–71.
   PubMed Web of Science ®Google Scholar
• Bell MJ, Stockwell DC, Luban NL, Shirey RS, Shaak L, Ness PM, et al.. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr Crit Care Med. 2005;6(3):363–6.
   PubMedGoogle Scholar
• Longo F, Hastier P, Buckley MJ, Chichmanian RM, Delmont JP. Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol. 1998;93(5):836–7.
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for ‘seronegative Lyme disease’. South Med J. 1991;84(10):1263–5.
   PubMed Web of Science ®Google Scholar
• Kaur I, Singh J. Cholestatic hepatitis with intravenous ceftriaxone. Indian J Pharmacol. 2011;43(4):474–5.
   PubMed Web of Science ®Google Scholar
• Ekiz F, Usküdar O, Simsek Z, Yüksel I, Basar O, Altinbas A, et al.. Cefuroxime axetil-induced liver failure. Ann Hepatol. 2010;9(3):306.
   PubMed Web of Science ®Google Scholar
• Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol. 2004;38(9):833.
   PubMed Web of Science ®Google Scholar
• Schreiber C, May B. Cholestasis in imipenem/cilastatin treatment. Z Gastroenterol. 1993;31(Suppl 2):76–7.
   PubMedGoogle Scholar
• Quattropani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver. 2001;21(3):213–6.
   PubMedGoogle Scholar
• Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy. 2010;30(9):953.
   PubMed Web of Science ®Google Scholar
• Johnson DF, Hall WH. Allergic hepatitis caused by propionyl erythromycin ester of lauryl sulfate. N Engl J Med. 1961;265:1200–2.
   PubMed Web of Science ®Google Scholar
• Havens WP. Cholestatic jaundice in patients treated with erythromycin estolate. JAMA. 1962;180:30–2;
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines. Jaundice and erythromycin, (adverse reactions series no. 10). London: DHSS; 1973.
   Google Scholar
• Strieker BH, Spoelstra P, editors. Drug-induced hepatic injury: a comprehensive survey of the literature on adverse drug reactions up to January 1985. Amsterdam: Elsevier; 1985. p. 153–4.
   Google Scholar
• Inman WH, Rawson NS. Erythromycin estolate and jaundice. Br Med J (Clin Res Ed). 1983;286(6382):1954–5.
   PubMedGoogle Scholar
• Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust. 1993;158(9):600–2.
   PubMed Web of Science ®Google Scholar
• Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al.. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576–83.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9.
   PubMed Web of Science ®Google Scholar
• Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, et al.. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992;15(2):244–51.
   PubMed Web of Science ®Google Scholar
• Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med. 1990;150(1):215–6.
   PubMedGoogle Scholar
• Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci. 1979;24(5):385–96.
   PubMed Web of Science ®Google Scholar
• Krowchuk D, Seashore JH. Complete biliary obstruction due to erythromycin estolate administration in an infant. Pediatrics. 1979;64(6):956–8.
   PubMed Web of Science ®Google Scholar
• Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol. 2005;39(8):743–4.
   PubMed Web of Science ®Google Scholar
• Horn S, Aglas F, Horina JH. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate recurrence following therapy with erythromycin succinate. Wien Klin Wochenschr. 1999;111(2):76–7.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother. 1985;16(Suppl A):181–94.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. 1999;20(1):25–41.
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Al-Nimr A, Whelan P. Azithromycin-induced hepatoxicity. Am J Med. 2005;118(12):1438–9.
   PubMed Web of Science ®Google Scholar
• Lockwood AM, Cole S, Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm. 2010;67(10):810–4.
   PubMed Web of Science ®Google Scholar
• Brown BA, Wallace RJ, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis. 1995;20(4):1073–4.
   PubMed Web of Science ®Google Scholar
• Fox JC, Szyjkowski RS, Sanderson SO, Levine RA. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol. 2002;42(6):676–80.
   PubMed Web of Science ®Google Scholar
• Masiá M, Gutiérrez F, Jimeno A, Navarro A, Borrás J, Matarredona J, et al.. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med. 2002;162(4):474–6.
   PubMedGoogle Scholar
• Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krähenbühl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother. 2003;37(1):57–60.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Sanchez-Martinez H, Perez-Serrano JM, Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J Gastroenterol. 1998;93(11):2309–11.
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med. 1991;91(6A):153S–61S.
   PubMedGoogle Scholar
• Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H, Kloppel G. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol. 1995;23(6):759–60.
   PubMed Web of Science ®Google Scholar
• Labowitz JK, Silverman WB. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci. 1997;42(1):192–4.
   PubMed Web of Science ®Google Scholar
• Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn’s disease. J Hepatol. 2002;37(5):696–9.
   PubMed Web of Science ®Google Scholar
• Goetz M, Galle PR, Schwarting A. Non-fatal acute liver injury possibly related to high-dose ciprofloxacin. Eur J Clin Microbiol Infect Dis. 2003;22(5):294–6.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Simon Z, Brezis M. Fatal hepatic failure associated with ciprofloxacin. Lancet. 1994;343(8899):738–9.
   PubMed Web of Science ®Google Scholar
• Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother. 1992;26(5):636–9.
   PubMed Web of Science ®Google Scholar
• Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy. Chemotherapy. 2001;47(Suppl 3):32–7.
   PubMedGoogle Scholar
• Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47(Suppl 3):9–14.
   PubMedGoogle Scholar
• Figueira-Coelho J, Pereira O, Picado B, Mendonça P, Neves-Costa J, Neta J. Acute hepatitis associated with the use of levofloxacin. Clin Ther. 2010;32(10):1733–7.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Levaquin: highlights of prescribing information [Internet]. Silver Spring (MD): FDA; 2008 [cited 2012 Jul 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
   Google Scholar
• Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN. Possible levofloxacin induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis. 2001;33(12):2088–90.
   PubMed Web of Science ®Google Scholar
• Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. J Hepatol. 2001;35(2):308–9.
   PubMed Web of Science ®Google Scholar
• Schwalm JD, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ. 2003;168(7):847–8.
   PubMed Web of Science ®Google Scholar
• Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. Ann Pharmacother. 2005;39(10):1737–40.
   PubMed Web of Science ®Google Scholar
• Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JR, Lavín AC, Mones JC, et al.. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumonia infection. Clin Ther. 2009;31(5):1014–9.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol. 2000;95(12):3662–4.
   PubMed Web of Science ®Google Scholar
• Jones SE, Smith RH. Quinolones may induce hepatitis. BMJ. 1997;314(7084):869.
   PubMedGoogle Scholar
• González Carro P, Huidobro ML, Zabala AP, Vicente EM. Fatal subfulminant hepatic failure with ofloxacin. Am J Gastroenterol. 2000;95(6):1606.
   PubMed Web of Science ®Google Scholar
• Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther. 2004;26(7):940–50.
   PubMed Web of Science ®Google Scholar
• Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf. 2005;28(5):443–52.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66(7):1431–46.
   PubMed Web of Science ®Google Scholar
• Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito I, Milano R. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics. 2010;126(5):e1253–6.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Moxifloxacin: European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines [Internet]. London: EMA; 2010 [cited 2012 Jul 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/news_and_events/news/2010/08/news_detail_001068.jsp&mid = WC0b01ac058004d5c1
   Google Scholar
• Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury: review of the literature and report of a case due to sulfamethoxazole. N Engl J Med. 1967;277(15):785–8.
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. 1995;15(4):428–32.
   PubMed Web of Science ®Google Scholar
• Bell TL, Foster JN, Townsend ML. Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient. Pharmacotherapy. 2010;30(5):539.
   PubMedGoogle Scholar
• Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100(4):495–9.
   PubMed Web of Science ®Google Scholar
• Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol. 1994;89(8):1230–4.
   PubMed Web of Science ®Google Scholar
• Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol. 1997;92(1):167–9.
   PubMed Web of Science ®Google Scholar
• Espiritu CR, Kim TS, Levine RA. Granulomatous hepatitis associated with sulfadimethoxine hypersensitivity. JAMA. 1967;202(10):985–8.
   PubMed Web of Science ®Google Scholar
• Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med. 1985;102(5):722.
   PubMed Web of Science ®Google Scholar
• Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am J Gastroenterol. 1989;84(12):1577–9.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology. 1981;80(4):816–9.
   PubMed Web of Science ®Google Scholar
• Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, et al.. Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole. Eur J Pediatr. 1995;154(7):530–3.
   PubMed Web of Science ®Google Scholar
• Ilario MJ, Ruiz JE, Axiotis CA. Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole. Arch Pathol Lab Med. 2000;124(12):1800–3.
   PubMed Web of Science ®Google Scholar
• Konttinen A, Peräsalo JO, Eisalo A. Sulfonamidehepatitis. Acta Med Scand. 1972;191(5):389–91.
   PubMedGoogle Scholar
• Lepper MH, Wolfe CK, Zimmerman HJ, Caldwell ER, Spies HW, Dowling HF. Effect of large doses of aureomycin on human liver. AMA Arch Intern Med. 1951;88(3):271–83.
   PubMedGoogle Scholar
• Schultz JC, Adamson JS, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med. 1963;269:999–1004.
   PubMed Web of Science ®Google Scholar
• Peters RL, Edmondson HA, Mikkelsen WP, Tatter D. Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. Am J Surg. 1967;113(5):622–32.
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Rywlin AM. Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis. 1970;15(9):857–62.
   PubMedGoogle Scholar
• Björnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol. 1997;32(4): 390–5.
   PubMed Web of Science ®Google Scholar
• Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483–7.
   PubMed Web of Science ®Google Scholar
• Chavant F, Lafay-Chebassier C, Beauchant M, Perault-Pochat MC. Doxycycline induced hepatitis. Gastroenterol Clin Biol. 2008;32(10):825–7.
   PubMedGoogle Scholar
• Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol. 2008;20(8):796–9.
   PubMed Web of Science ®Google Scholar
• Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312(7024):169–72.
   PubMedGoogle Scholar
• Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23(4):333–49.
   PubMed Web of Science ®Google Scholar
• Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66.
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Am J Clin Pathol. 2000;114(4):591–8.
   PubMed Web of Science ®Google Scholar
• Edoute Y, Karmon Y, Roguin A, Ben-Ami H. Fatal liver necrosis associated with the use of nitrofurantoin. Isr Med Assoc J. 2001;3(5):382–3.
   PubMed Web of Science ®Google Scholar
• Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology. 1981;18(2):177–8.
   PubMed Web of Science ®Google Scholar
• Stricker BH, Blok AP, Claas FH, van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8(3):599–606.
   PubMed Web of Science ®Google Scholar
• D’Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm. 1985;19(7–8):540–7.
   PubMedGoogle Scholar
• Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol. 2004;172(2):448–53.
   PubMed Web of Science ®Google Scholar
• Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med. 1974;57(4):627–30.
   PubMed Web of Science ®Google Scholar
• Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J Gastroenterol. 2007;13(40):5408–10.
   PubMed Web of Science ®Google Scholar
• Sahagún Flores JE, Soto Ortiz JA, Tovar Méndez CE, Cárdenas Ochoa EC, Hernández Flores G. Stevens–Johnson syndrome plus intrahepatic cholestasis caused by clindamycin or chlorpheniramine. Dermatol Online J. 2009;15(5):12.
   PubMedGoogle Scholar
• Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother. 2006;40(6):1186–9.
   PubMed Web of Science ®Google Scholar
• Mennicke M, Zawodniak A, Keller M, Wilkens L, Yawalkar N, Stickel F, et al.. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant. 2009;9(9):2197–202.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang XY, Zeckel M, Killian C, Hornbuckle K, Regev A, et al.. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf. 2011;34(1):73–82.
   PubMed Web of Science ®Google Scholar
• de Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, et al.. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322–6.
   PubMedGoogle Scholar
• Food and Drug Administration. Ketek: product label information [Internet]. Silver Spring (MD): FDA; 2004 [cited 2012 Jul 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21144_ketek_lbl.pdf
   Google Scholar
• Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144(6):415–20.
   PubMed Web of Science ®Google Scholar
• Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin Ther. 2007;29(8):1725–9.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513–39.
   PubMed Web of Science ®Google Scholar
• Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, et al.. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009;49(1):250–7.
   PubMed Web of Science ®Google Scholar
• Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 2000;22(7):798–817.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Rodrigo L, Salmerón J, Alvarez A, Lopez-Garrido MJ, et al.. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 2000;30(2):400–1.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Public statement on trovafloxacin/alatrofloxacin: recommendation to suspend the marketing authorisation in the European Union [Internet]. London: EMA; 2009 [cited 2012 Jul 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018300.pdf
   Google Scholar
• European Medicines Agency. Better medicines for children [Internet]. London: EMA; 2009 [cited 2013 Mar 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500026493.pdf
   Google Scholar
• Liver injury by antibiotics. Br Med J. 1953;1(4813):777.
   PubMedGoogle Scholar
• Shibl AM, Memish Z, Osoba A. Antibiotic resistance in developing countries. J Chemother. 2001;13(Suppl 1):40–4.
   PubMedGoogle Scholar
• Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3(2):e16.
   PubMedGoogle Scholar
• Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;(1):CD002086;
   Google Scholar
• Chiappini E, Regoli M, Bonsignori F, Sollai S, Parretti A, Galli L, et al.. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther. 2011;33(1):48–58.
   PubMed Web of Science ®Google Scholar
• Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol. 2010;245(1):134–42.
   PubMed Web of Science ®Google Scholar